[go: up one dir, main page]

US20030064081A1 - Topical anti-pruritic composition - Google Patents

Topical anti-pruritic composition Download PDF

Info

Publication number
US20030064081A1
US20030064081A1 US10/227,894 US22789402A US2003064081A1 US 20030064081 A1 US20030064081 A1 US 20030064081A1 US 22789402 A US22789402 A US 22789402A US 2003064081 A1 US2003064081 A1 US 2003064081A1
Authority
US
United States
Prior art keywords
composition
topical
antiallergenic
inflammatory drug
proprionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/227,894
Inventor
William Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/227,894 priority Critical patent/US20030064081A1/en
Publication of US20030064081A1 publication Critical patent/US20030064081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 

Definitions

  • the present invention relates to the treatment of skin conditions caused by exposure to allergens resulting in allergic reactions.
  • allergen sources and their subsequent skin reactions include poison ivy, poison oak, poison sumac, mosquito bites, eczema and other allergic skin reactions.
  • the present invention comprises a topical antiallergenic composition
  • a topical antiallergenic composition comprising as its principle ingredient a proprionic acid nonsteroidal anti-inflammatory drug. It is surprising to find that proprionic acid nonsteroidal anti-inflammatory drugs show topical antiallergenic properties.
  • a proprionic acid nonsteroidal anti-inflammatory drug is prepared in a suitable topical form.
  • the various topical forms include a paste, cream, gel or liquid.
  • Medications included in the class of proprionic acid nonsteroidal anti-inflammatory drugs are fenoprofen, fluribuprofen, ibuprofen, ketoprofen and naproxen, and their corresponding pharmaceutically acceptable salts.
  • the dosage of active per gram of paste, cream, gel or liquid is approximately the same as the active dosage per gram in the tablet form of the same active.
  • the ibuprofen topical dosage range is from about 150 mg to about 850 mg per gram of product
  • the fenoprofen topical dosage range is from about 550 mg to about 650 mg per gram
  • the fluribuprofen topical range is from about 10 mg to about 150 mg per gram
  • the ketoprofen topical dosage range is from about 10 mg to about 75 mg per gram
  • the naproxen topical dosage range is from about 170 to about 600 mg per gram.
  • the most preferred proprionic acid nonsteroidal anti-inflammatory drug known at present time is ibuprofen.
  • the most preferred form known at the present time is a cream or paste.
  • the cream or paste can be made for example by adding water to the conventional proprionic acid nonsteroidal anti-inflammatory tablets. More specifically, the cream or paste can be made by combining 6 drops of hot tap water (100-150° F.) with three 200 mg ibuprofen tablets. From the onset of said combination to approximately 15 minutes thereafter, stirring occasionally, the hot water will cause the dissolution of the ibuprofen tablets. A thick pourable consistency will result with an approximate tablet weight to water volume ratio of 10000:1. Conceivably, one may also use ibuprofen powder as a source of the proprionic acid nonsteroidal anti-inflammatory drug.
  • ingredients in a paste or cream made directly from the tablets include excipients such as Carnauba wax, corn starch, hydroxypropyl methylcellulose, propylene glycol, silicon dioxide, pregelatinized starch, stearic acid, titanium dioxide, iron oxide black, as well as the proprionic acid nonsteroidal anti-inflammatory drug as the active ingredient.
  • excipients such as Carnauba wax, corn starch, hydroxypropyl methylcellulose, propylene glycol, silicon dioxide, pregelatinized starch, stearic acid, titanium dioxide, iron oxide black, as well as the proprionic acid nonsteroidal anti-inflammatory drug as the active ingredient.
  • water is the carrier while the tablet polymetric coating material makes the paste more cream like.
  • Other pharmaceutical carriers that might be used include petrolatum, lanolin, Aquaphor®, Polysorb, Nivea® cream and polyethylene glycol.
  • the product of the preferred embodiment is effective against itching resulting from poison ivy, poison oak, poison sumac, mosquito bites, eczema and other allergic skin reactions.
  • dissipation of the underlying source of itch can be expected within two to four days.
  • a person can expect relief of itch symptoms within 5 to 15 minutes of topical application.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A topical antiallergenic composition and methods for treatment are provided. A proprionic acid nonsteroidal anti-inflammatory drug is prepared in a suitable topical form for the treatment of skin conditions caused by allergic reactions. The various allergic reactions include poison ivy, poison oak, poison sumac, mosquito bites, eczema and other allergic skin reactions.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims the benefit of U.S. Provisional Application No. 60/326,273, entitled TOPICAL ANTI-PRURITIC COMPOSITION, filed Oct. 1, 2001. [0001]
  • BACKGROUND OF THE INVENTION
  • The present invention relates to the treatment of skin conditions caused by exposure to allergens resulting in allergic reactions. Such allergen sources and their subsequent skin reactions include poison ivy, poison oak, poison sumac, mosquito bites, eczema and other allergic skin reactions. [0002]
  • Exposure to such allergens results in some of the most common topical allergic reactions in the United States. There are a variety of conventional products used to treat poison ivy, poison oak, poison sumac, mosquito bites, eczema and other allergic skin reactions. Typical products include oral antihistamines, such as Claritin® or Diphenhydramine, and/or a corticosteroid with anti-inflammatory properties, such as Prednisone. There are several topical products also available including topical antihistamine products, such as Diphenhydramine containing medicaments, and topical steroid products, such as Betamethasone or Hydrocortisone containing medicaments. Additional products used in topical treatment include antipruritic products, such as Calamine containing medicaments, cleansing wipes for removal of an allergen, or topical astringent solutions such as Domeboro®. [0003]
  • SUMMARY OF THE INVENTION
  • The present invention comprises a topical antiallergenic composition comprising as its principle ingredient a proprionic acid nonsteroidal anti-inflammatory drug. It is surprising to find that proprionic acid nonsteroidal anti-inflammatory drugs show topical antiallergenic properties. [0004]
  • These and other features, advantages, and objects of the present invention will be further understood and appreciated by those skilled in the art by reference to the following specification and claims. [0005]
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENT
  • In the product of the preferred embodiment, a proprionic acid nonsteroidal anti-inflammatory drug is prepared in a suitable topical form. The various topical forms include a paste, cream, gel or liquid. Medications included in the class of proprionic acid nonsteroidal anti-inflammatory drugs are fenoprofen, fluribuprofen, ibuprofen, ketoprofen and naproxen, and their corresponding pharmaceutically acceptable salts. [0006]
  • The dosage of active per gram of paste, cream, gel or liquid is approximately the same as the active dosage per gram in the tablet form of the same active. Thus, the ibuprofen topical dosage range is from about 150 mg to about 850 mg per gram of product, the fenoprofen topical dosage range is from about 550 mg to about 650 mg per gram, the fluribuprofen topical range is from about 10 mg to about 150 mg per gram, the ketoprofen topical dosage range is from about 10 mg to about 75 mg per gram and the naproxen topical dosage range is from about 170 to about 600 mg per gram. [0007]
  • The most preferred proprionic acid nonsteroidal anti-inflammatory drug known at present time is ibuprofen. The most preferred form known at the present time is a cream or paste. [0008]
  • The cream or paste can be made for example by adding water to the conventional proprionic acid nonsteroidal anti-inflammatory tablets. More specifically, the cream or paste can be made by combining 6 drops of hot tap water (100-150° F.) with three 200 mg ibuprofen tablets. From the onset of said combination to approximately 15 minutes thereafter, stirring occasionally, the hot water will cause the dissolution of the ibuprofen tablets. A thick pourable consistency will result with an approximate tablet weight to water volume ratio of 10000:1. Conceivably, one may also use ibuprofen powder as a source of the proprionic acid nonsteroidal anti-inflammatory drug. [0009]
  • Ingredients in a paste or cream made directly from the tablets include excipients such as Carnauba wax, corn starch, hydroxypropyl methylcellulose, propylene glycol, silicon dioxide, pregelatinized starch, stearic acid, titanium dioxide, iron oxide black, as well as the proprionic acid nonsteroidal anti-inflammatory drug as the active ingredient. [0010]
  • In the above formula, water is the carrier while the tablet polymetric coating material makes the paste more cream like. Other pharmaceutical carriers that might be used include petrolatum, lanolin, Aquaphor®, Polysorb, Nivea® cream and polyethylene glycol. [0011]
  • The product of the preferred embodiment is effective against itching resulting from poison ivy, poison oak, poison sumac, mosquito bites, eczema and other allergic skin reactions. Upon topical application of the product of the preferred embodiment, dissipation of the underlying source of itch can be expected within two to four days. Generally, a person can expect relief of itch symptoms within 5 to 15 minutes of topical application. [0012]
  • The above description is considered that of the preferred embodiments only. Modifications of the invention will occur to those skilled in the art and to those who make or use the invention. Therefore, it is understood that the embodiments described above is/are merely for illustrative purposes and not intended to limit the scope of the invention, which is defined by the following claims as interpreted according to the principles of patent law, including the Doctrine of Equivalents. [0013]

Claims (18)

The invention claimed is:
1- A topical antiallergenic composition comprising as its principle ingredient a proprionic acid nonsteroidal anti-inflammatory drug.
2- The topical antiallergenic composition of claim 1, wherein said proprionic acid nonsteroidal anti-inflammatory drug is ibuprofen.
3- The topical antiallergenic composition of claim 1, wherein said composition is in a paste form.
4- The topical antiallergenic composition of claim 1, wherein said composition is in a cream form.
5- The topical antiallergenic composition of claim 1, wherein said composition is in a gel form.
6- The topical antiallergenic composition of claim 1, wherein said preferred composition is in a liquid form.
7- A process for producing the topical antiallergenic composition of claim 1, wherein water is heated to a temperature of 100 to 150 degrees Fahrenheit; the heated water is then added to said proprionic acid non-steroidal anti-inflammatory drug ibuprofen.
8- A method for treating allergic skin reactions comprising:
applying to the affected area of the skin a topical antiallergenic composition containing as its principle ingredient a proprionic acid nonsteroidal anti-inflammatory drug.
9- The method of claim 8, wherein the allergic skin reaction is poison ivy.
10- The method of claim 8, wherein the allergic skin reaction is poison oak.
11- The method of claim 8, wherein the allergic skin reaction is poison sumac.
12- The method of claim 8, wherein the allergic skin reaction is caused by mosquito bites.
13- The method of claim 8, wherein the allergic skin reaction is eczema.
14- The method of claim 8, wherein said proprionic acid nonsteroidal anti-inflammatory drug is ibuprofen.
15- The method of claim 8, wherein said composition is in a paste form.
16- The method of claim 8, wherein said composition is in a cream form.
17- The method of claim 8, wherein said composition is in a gel form.
18- The method of claim 8, wherein said preferred composition is in a liquid form.
US10/227,894 2001-10-01 2002-08-26 Topical anti-pruritic composition Abandoned US20030064081A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/227,894 US20030064081A1 (en) 2001-10-01 2002-08-26 Topical anti-pruritic composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32627301P 2001-10-01 2001-10-01
US10/227,894 US20030064081A1 (en) 2001-10-01 2002-08-26 Topical anti-pruritic composition

Publications (1)

Publication Number Publication Date
US20030064081A1 true US20030064081A1 (en) 2003-04-03

Family

ID=26921854

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/227,894 Abandoned US20030064081A1 (en) 2001-10-01 2002-08-26 Topical anti-pruritic composition

Country Status (1)

Country Link
US (1) US20030064081A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177406A1 (en) * 2005-02-08 2006-08-10 Niazi Sarfaraz K Formula, a system and a method for treating urushiol induced contact dermatitis
CN102824359A (en) * 2011-06-17 2012-12-19 张廷兴 Mosquito-toxin-removing liniment
CN102949297A (en) * 2012-06-14 2013-03-06 江西农业大学 Mosquito repellent gel and preparation method thereof
CN109152753A (en) * 2016-05-17 2019-01-04 拥护者生物技术有限公司 For treating/preventing dermopathic carboxylic acid
EP3458158A4 (en) * 2016-05-18 2020-02-05 Dermala Inc. COMPOSITIONS AND METHODS FOR TREATING ECZEM

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623667A (en) * 1985-06-28 1986-11-18 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623667A (en) * 1985-06-28 1986-11-18 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177406A1 (en) * 2005-02-08 2006-08-10 Niazi Sarfaraz K Formula, a system and a method for treating urushiol induced contact dermatitis
CN102824359A (en) * 2011-06-17 2012-12-19 张廷兴 Mosquito-toxin-removing liniment
CN102949297A (en) * 2012-06-14 2013-03-06 江西农业大学 Mosquito repellent gel and preparation method thereof
CN109152753A (en) * 2016-05-17 2019-01-04 拥护者生物技术有限公司 For treating/preventing dermopathic carboxylic acid
EP3458158A4 (en) * 2016-05-18 2020-02-05 Dermala Inc. COMPOSITIONS AND METHODS FOR TREATING ECZEM

Similar Documents

Publication Publication Date Title
CN119318707A (en) Methods of reducing side effects of administration of phosphodiesterase-4 inhibitors
DE3873879T2 (en) NON-SEDATIVE ANTIHISTAMINICA CONTAINING COUGH / SNUGS.
EP2373346B1 (en) Ibuprofen for topical administration
Ford et al. Pityrosporum folliculitis and ketoconazole
JPH02500107A (en) Fast-acting/enhanced analgesic effect
JPH10512851A (en) Prevention and therapeutic treatment of skin sensitization and irritation
JPH02501739A (en) steroid lotion
HU227207B1 (en) Use of a pharmaceutical combination of ethinylestradiol and drospirenone for producing pharmaceutical compositions having contraceptive activity
JPH06504543A (en) Orally administrable pharmaceutical formulation for treating central dopamine deficiency conditions
Shackel et al. Copper‐salicylate gel for pain relief in osteoarthritis: a randomised controlled trial
EP0784975B1 (en) Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries
JP3018160B2 (en) Drug for reducing dysmenorrhea and / or premenstrual syndrome
JPS6357405B2 (en)
US20030064081A1 (en) Topical anti-pruritic composition
US20210038548A1 (en) Composition and method for compounded therapy
JPH03204815A (en) Therapeutic composition for treating dermatological disease carried by mast cell
RU2101014C1 (en) Analgetic, antiinflammatory, antipyretic medicinal agent and a method of its preparing
JP2003531113A (en) Dual inhibitors of cholesterol ester and wax ester synthesis for sebaceous gland disorders
HUP0204208A2 (en) Antipruritic agents for external use
JPH03227921A (en) Remedy for keloid
AU2004262934B2 (en) Topical composition comprising terbinafine and hydrocortisone
DE19849737A1 (en) Combination agent for the treatment of inflammatory bowel disease
JPH06305962A (en) Atopic dermatitis therapeutic agent
Davis Scientific principles in design of drug dosage formulations
RU2426540C1 (en) Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION